Studies of a Prophylactic HIV-1 Vaccine Candidate Based on Modified Vaccinia Virus Ankara (MVA) with and without DNA Priming: Effects of Dosage and Route on Safety and Immunogenicity. Vaccine, 25, 2120-2127. presented at the 03/2007. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/17250931. (2007).
Safety and Immunogenicity of MVA.HIVA by 3 Different Routes. In AIDS Vaccine 2005 International Conference. presented at the 06/09/2005, Montreal, Quebec, Canada.. (2005).